N-(3-chloro-4-methylphenyl)-N'-(1,3-thiazol-2-yl) urea | 275800-96-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-chloro-4-methylphenyl)-N'-(1,3-thiazol-2-yl) urea
• 英文别名: N-(3-chloro-4-methylphenyl)-N'-(1,3-thiazol-2-yl)-urea；n-(3-Chloro-4-methylphenyl)-n'-(1,3-thiazol-2-yl)urea；1-(3-chloro-4-methylphenyl)-3-(1,3-thiazol-2-yl)urea
• CAS: 275800-96-9
• 化学式: C₁₁H₁₀ClN₃OS
• 分子量: 267.739
• InChiKey: NQBOGPVBALKGGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  82.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氨基噻唑 、 3-氯-4-甲基苯基异氰酸酯 以 二甲基亚砜 为溶剂， 生成 N-(3-chloro-4-methylphenyl)-N'-(1,3-thiazol-2-yl) urea
  参考文献：
  名称：

  Evaluation of Diarylureas for Activity Against Plasmodium falciparum

  摘要：

  A library of diarylurea insulin-like growth factor 1 receptor inhibitors was screened for activity against chloroquine-sensitive (3D7) and chloroquine-resistant (K1) strains of Plasmodium falciparum. The 4-aminoquinaldine-derived diarylureas displayed promising antimalarial potency. Further exploration of the B ring of 4-aminoquinaldinyl ureas allowed identification of several quinaldin-4-yl ureas 4{13, 39} and 4{13, 58) sufficiently potent against both 3D7 and K1 strains to qualify as bone fide leads.

  DOI：

  10.1021/ml100083c

文献信息

• [EN] HETEROARYL-ARYL UREAS AS IGF-1 RECEPTOR ANTAGONISTS<br/>[FR] UREES HETEROARYLE-ARYLE UTILISEES COMME ANTAGONISTES DU RECEPTEUR IGF-1
  申请人：TELIK INC

  公开号：WO2000035455A1

  公开（公告）日：2000-06-22

  Methods for treating diseases associated with the activity of the insulin growth factor-1 receptor (IGF-1R), such as cancer, are provided. Methods for inhibiting cell growth and proliferation, especially of tumor cells, and promoting apoptosis are also provided. Each of these methods employs the use of a heteroaryl-aryl urea compound as an antagonist for IGF-1R.

  提供了一种治疗与胰岛素生长因子-1受体（IGF-1R）活性相关的疾病，如癌症的方法。还提供了一种抑制细胞生长和增殖，特别是肿瘤细胞，并促进细胞凋亡的方法。每种方法都使用杂环芳基脲化合物作为IGF-1R的拮抗剂。
• METHODS, COMPOUNDS AND COMPOSITIONS WITH GENOTYPE SELECTIVE ANTICANCER ACTIVITY
  申请人：Von Hoff Daniel D.

  公开号：US20090137420A1

  公开（公告）日：2009-05-28

  This invention is directed to methods for screening and identification of compounds capable of selectively eliminating cancer cells with specific loss-of-function alterations, including but not limited to mutations, deletions, hypermethylations, and other types of gene silencing. This invention is also directed to novel compounds that selectively eliminate cancer cells with specific loss-of-function alterations. Furthermore, this invention is directed to methods for production and therapeutic use of compounds that selectively eliminate cancer cells with specific loss-of-function alterations.

  这项发明涉及筛选和鉴定能够有选择性地消除带有特定失活改变的癌细胞的化合物的方法，包括但不限于突变、缺失、高甲基化和其他类型的基因沉默。这项发明还涉及具有选择性消除带有特定失活改变的癌细胞的新型化合物。此外，这项发明还涉及生产和治疗使用具有选择性消除带有特定失活改变的癌细胞的化合物的方法。
• US6337338B1
  申请人：——

  公开号：US6337338B1

  公开（公告）日：2002-01-08
• US8394742B2
  申请人：——

  公开号：US8394742B2

  公开（公告）日：2013-03-12